AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

Bio NC

Best Places to Work in Biopharma 2023 Report Reveals Most Sought-After Employers

BioSpace’s 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership.

November 11, 2022

5 min read

BioSpace Editorial Staff

Drug Development

AbbVie Touts Subgroup Data in Phase II Atrial Fibrillation Miss

AbbVie’s investigational neurotoxin, designed to prevent postoperative atrial fibrillation, missed the primary endpoint in a Phase II trial, the company announced Monday.

November 8, 2022

2 min read

Tristan Manalac

SKYRIZI is the new option for psoriatic arthritis.

Business

AbbVie Drops Autoimmune Candidate, Prioritizes Skyrizi and Rinvoq

While reporting stellar third-quarter financials, AbbVie announced it was halting development of cedirogant and provided updates on Skyrizi, Rinvoq and Humira.

October 31, 2022

3 min read

Mark Terry

Deals

AbbVie Gains Access to Pulmonary Fibrosis Antibody with $225M DJS Buy

AbbVie is buying DJS Antibodies for $225 million in cash to gain access to the British company’s potential fibrotic diseases drug and antibody discovery program.

October 20, 2022

2 min read

Mark Terry

BioMidwest

10 Reasons to Keep an Eye on Chicago Biotech in 2023

Between top-notch academic institutions, solid venture capital funding, expanding lab space and governmental support, Chicago is emerging as a true hotbed for biotech growth.

October 18, 2022

5 min read

Lisa Munger

Drug Development

AAO 2022: Janssen, REGENXBIO, Apellis and More

Gene therapies developed by Janssen, Atsena, REGENXBIO and AbbVie showed promise against eye diseases this weekend at the American Academy of Ophthalmology 2022 meeting.

October 3, 2022

3 min read

Tristan Manalac

Biotech Bay

Remote Work Opportunities Abound at Pfizer, GRAIL, Regeneron and More

In a recent BioSpace poll, more than half of employers indicated they planned to continue recruiting employees remotely. We highlight just some of those jobs here.

September 21, 2022

5 min read

Lisa Munger

Drug Development

Research Ramps Up in Alzheimer’s, Parkinson’s, MS and ALS

Research on Alzheimer’s, specifically in neuroscience, continues with the Alzheimer’s Drug Discovery Foundation, Critical Path Institute, Abbvie, AlzeCure Pharma and more.

September 19, 2022

4 min read

Paul Elias